JTP 4819

Subscribe to Selected New Research on JTP 4819

6 relevant articles (3 outcomes, 2 trials/studies) found for this Bio-Agent

Description: a prolyl endopeptidase inhibitor; structure given in first source

Also Known As:

2-((2-(hydroxyacetyl)-1-pyrrolidinyl)carbonyl)-N-(phenylmethyl)-1-pyrrolidinecarboxamide; JTP-4819

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Pyrrolidines: 4

JTP 4819: 6

Related Diseases

1.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/03/1996 - "These results suggest that JTP-4819 ameliorates memory impairment due to middle cerebral artery occlusion by restoring the cortical TRH content." 06/03/1996 - "The prolonged escape latency in the Morris water maze task in rats with middle cerebral artery occlusion was also significantly reduced by administration of JTP-4819 (0.3 and 1 mg/kg p.o.)" 06/03/1996 - "Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion." 06/03/1996 - "Administration of JTP-4819 (0.1 and 1 mg/kg p.o for 7 days) significantly prolonged passive avoidance latency, while the latency of rats with middle cerebral artery occlusion receiving the vehicle was significantly shorter than that of sham-operated rats" Get all the results and reference details, order at left...
2.	Amnesia (Dissociative Amnesia) 09/01/1995 - "In the one-trial passive avoidance test in rats with scopolamine-induced amnesia, JTP-4819 significantly prolonged the retention time when administered orally at doses of 1 and 3 mg/kg 1 hr before acquisition or at 3 and 10 mg/kg 1 hr before retention" 09/01/1995 - "In addition, coadministration of JTP-4819 and substance P, arginine-vasopressin or thyrotropin-releasing hormone (at doses at which each drug alone did not prolong the retention time) improved the retention time of rats with scopolamine-induced amnesia" Get all the results and reference details, order at left...
3.	Memory Disorders (Memory Loss) 03/01/1997 - "Administration of JTP-4819 (1 mg/kg, p.o.) for 14 days improved this memory deficit in aged rats, as shown by the decrease in escape latency and path length" Get all the results and reference details, order at left...
4.	Alzheimer Disease (Alzheimer's Disease) 02/01/1997 - "Taken together, these unique and potent pharmacological actions of JTP-4819 suggest that it may have the potential to be used for treating Alzheimer's disease." 01/01/1998 - "In this report, the pharmacological actions of JTP-4819, a novel specific prolyl endopeptidase (PEP) inhibitor devised for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, neuropeptidergic and cholinergic neurons, and memory-related behavior in rats" 02/01/1997 - "A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease." 02/01/1997 - "The pharmacological actions of JTP-4819, a new prolyl endopeptidase (PEP) inhibitor targeted for the treatment of Alzheimer's disease, are reviewed with respect to its effects on PEP activity, brain neurotransmitters, and memory-related behaviour in rats" Get all the results and reference details, order at left...
5.	Neuroblastoma 12/01/2006 - "We studied the ability of prolyl oligopeptidase (POP) inhibitors, Z-Pro-Prolinal and JTP-4819, to prevent translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and formation of reactive oxygen species (ROS), in 6-hydroxydopamine (6-OHDA) and cytosine arabinoside (Ara-C) treated monkey fibroblast (CV1-P) and human neuroblastoma (SH-SY5Y) cells" Get all the results and reference details, order at left...
5 Diseases and 6 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Scopolamine (Hyoscine)
2.	Thyrotropin-Releasing Hormone (Prolactin Releasing Hormone)
3.	Substance P
4.	Arginine Vasopressin (Argipressin)
5.	prolyl oligopeptidase (prolyl endopeptidase)
6.	Neurotransmitter Agents (Neurotransmitter)
7.	Reactive Oxygen Species (Oxygen Radicals)
8.	Oxidopamine (6 Hydroxydopamine)
9.	Oxidoreductases
10.	Cytarabine (Cytosar-U)
12 Drugs and Important Bio-Agents and 5 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>